Clinical Trials Directory

Trials / Conditions / Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

13 registered clinical trials studyying Advanced Head and Neck Squamous Cell Carcinoma — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingMorning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum
NCT07405086
OHSU Knight Cancer InstitutePhase 2
RecruitingIvonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
NCT07094685
University of Michigan Rogel Cancer CenterPhase 2
CompletedInfluencing Factors for Physical Activity in People With Head and Neck Cancer
NCT06272513
Kantonsspital Winterthur KSW—
RecruitingA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell
NCT05910827
Hummingbird BiosciencePhase 1 / Phase 2
WithdrawnPembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell
NCT05743777
Canadian Cancer Trials GroupPhase 2
CompletedA Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of
NCT05383170
Cytovation ASPhase 1 / Phase 2
SuspendedComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advan
NCT05050162
NRG OncologyPhase 2 / Phase 3
Active Not RecruitingTesting the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cance
NCT04533750
National Cancer Institute (NCI)Phase 1
CompletedDuvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05057247
Glenn J. HannaPhase 2
RecruitingIACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT05039801
M.D. Anderson Cancer CenterPhase 1
CompletedQuad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
NCT04454489
Wake Forest University Health SciencesPhase 2
TerminatedA Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT03254927
Celldex TherapeuticsPhase 2
Active Not RecruitingCIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or
NCT02955290
Roswell Park Cancer InstitutePhase 1 / Phase 2